A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer-Reference-Cited by-同舟云学术

A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer

Published:2021-12-10 Issue:12 Volume:4 Page:e2138432
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Anderson Eric¹,LeVee Alexis²,Kim Sungjin³,Atkins Katelyn¹,Guan Michelle²,Placencio-Hickok Veronica²,Moshayedi Natalie²,Hendifar Andrew²,Osipov Arsen²,Gangi Alexandra⁴,Burch Miguel⁴,Waters Kevin⁵,Cho May⁶,Klempner Samuel⁷,Chao Joseph⁸,Kamrava Mitchell¹,Gong Jun²

Affiliation:

1. Department of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, California

2. Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California

3. Biostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California

4. Division of Surgical Oncology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California

5. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

6. Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Irvine, California

7. Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts

8. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2787000/anderson_2021_oi_211083_1638542630.3157.pdf

Reference35 articles.

1. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial.;Boige;J Clin Oncol,2007

2. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.;Cunningham;N Engl J Med,2006

3. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.;Ychou;J Clin Oncol,2011

4. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.;Bang;Lancet,2012

5. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.;Sakuramoto;N Engl J Med,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locally Advanced Gastric Cancer Management: A Cost-Effectiveness Analysis;The American Surgeon™;2024-01-15

2. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer;2023-12-12

3. PREOPERATIVE CHEMOTHERAPY VERSUS UPFRONT SURGERY FOR ADVANCED GASTRIC CANCER: A PROPENSITY SCORE MATCHING ANALYSIS;ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo);2023

4. Gastric Cancer;Gastroenterology Clinics of North America;2022-09

5. Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis;Frontiers in Oncology;2022-08-05